PAGANO, Livio, Jon SALMANTON-GARCIA, Francesco MARCHESI, Ola BLENNOW, da Silva Maria GOMES, Andreas GLENTHOJ, van Doesum JAAP, Yavuz M BILGIN, Alberto LOPEZ-GARCIA, Federico ITRI, Raquel Nunes RODRIGUES, Barbora WEINBERGEROVA, Francesca FARINA, Giulia DRAGONETTI, Caroline Berg VENEMYR, van Praet JENS, Ozren JAKSIC, Toni VALKOVIC, Iker FALCES-ROMERO, Sonia MARTIN-PEREZ, Moraima JIMENEZ, Julio DAVILA-VALLS, Martin SCHONLEIN, Emanuele AMMATUNA, Stef MEERS, Mario DELIA, Zlate STOJANOSKI, Anna NORDLANDER, Tobias LAHMER, Laszlo Imre PINCZES, Caterina BUQUICCHIO, Klara PIUKOVICS, Irati ORMAZABAL-VELEZ, Nicola FRACCHIOLLA, Michail SAMARKOS, Gustavo-Adolfo MENDEZ, Jose-Angel HERNANDEZ-RIVAS, Ildefonso ESPIGADO, Martin CERNAN, Verena PETZER, Sylvain LAMURE, di Blasi ROBERTA, de Almedia Joyce MARQUES, Michelina DARGENIO, Monika M BIERNAT, Mariarita SCIUME, de Ramon CRISTINA, de Jonge NICK, Josip BATINIC, Avinash AUJAYEB, Monia MARCHETTI, Guillemette FOUQUET, Noemi FERNANDEZ, Giovanni ZAMBROTTA, Maria Vittoria SACCHI, Anna GUIDETTI, Fatih DEMIRKAN, Lucia PREZIOSO, Zdeněk RÁČIL, Marcio NUCCI, Milos MLADENOVIC, Raphael LIEVIN, Michaela HANAKOVA, Stefanie GRAFE, Uluhan SILI, Marina MACHADO, Chiara CATTANEO, Tatjana ADZIC-VUKICEVIC, Luisa VERGA, Jorge LABRADOR, Laman RAHIMLI, Matteo BONANNI, Francesco PASSAMONTI, Antonio PAGLIUCA, Paolo CORRADINI, Martin HOENIGL, Philipp KOEHLER, Alessandro BUSCA a Oliver A CORNELY. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. Washington DC, USA: American Society of Hematology, 2022, roč. 140, č. 26, s. 2773-2787. ISSN 0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood.2022017257.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Autoři PAGANO, Livio (garant), Jon SALMANTON-GARCIA, Francesco MARCHESI, Ola BLENNOW, da Silva Maria GOMES, Andreas GLENTHOJ, van Doesum JAAP, Yavuz M BILGIN, Alberto LOPEZ-GARCIA, Federico ITRI, Raquel Nunes RODRIGUES, Barbora WEINBERGEROVA, Francesca FARINA, Giulia DRAGONETTI, Caroline Berg VENEMYR, van Praet JENS, Ozren JAKSIC, Toni VALKOVIC, Iker FALCES-ROMERO, Sonia MARTIN-PEREZ, Moraima JIMENEZ, Julio DAVILA-VALLS, Martin SCHONLEIN, Emanuele AMMATUNA, Stef MEERS, Mario DELIA, Zlate STOJANOSKI, Anna NORDLANDER, Tobias LAHMER, Laszlo Imre PINCZES, Caterina BUQUICCHIO, Klara PIUKOVICS, Irati ORMAZABAL-VELEZ, Nicola FRACCHIOLLA, Michail SAMARKOS, Gustavo-Adolfo MENDEZ, Jose-Angel HERNANDEZ-RIVAS, Ildefonso ESPIGADO, Martin CERNAN, Verena PETZER, Sylvain LAMURE, di Blasi ROBERTA, de Almedia Joyce MARQUES, Michelina DARGENIO, Monika M BIERNAT, Mariarita SCIUME, de Ramon CRISTINA, de Jonge NICK, Josip BATINIC, Avinash AUJAYEB, Monia MARCHETTI, Guillemette FOUQUET, Noemi FERNANDEZ, Giovanni ZAMBROTTA, Maria Vittoria SACCHI, Anna GUIDETTI, Fatih DEMIRKAN, Lucia PREZIOSO, Zdeněk RÁČIL (203 Česká republika, domácí), Marcio NUCCI, Milos MLADENOVIC, Raphael LIEVIN, Michaela HANAKOVA (203 Česká republika), Stefanie GRAFE, Uluhan SILI, Marina MACHADO, Chiara CATTANEO, Tatjana ADZIC-VUKICEVIC, Luisa VERGA, Jorge LABRADOR, Laman RAHIMLI, Matteo BONANNI, Francesco PASSAMONTI, Antonio PAGLIUCA, Paolo CORRADINI, Martin HOENIGL, Philipp KOEHLER, Alessandro BUSCA a Oliver A CORNELY.
Vydání Blood, Washington DC, USA, American Society of Hematology, 2022, 0006-4971.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30205 Hematology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 20.300
Kód RIV RIV/00216224:14110/22:00128761
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1182/blood.2022017257
UT WoS 000922296500001
Klíčová slova anglicky COVID-19; patients with hematologic malignancies
Štítky 14110515, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 28. 2. 2023 14:52.
Anotace
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccination. Adult patients with HM, >= 1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received <= 2 vaccine doses before COVID-19 (1419, 91%), mostly mRNAbased (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P <.001), active HM (P <.001), and severe and critical COVID-19 (P =.007 and P <.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P <.001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P <.001) or combined with antivirals (P =.009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.
VytisknoutZobrazeno: 10. 9. 2024 09:17